Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)

Italy · Delayed Price · Currency is EUR

51.20

+0.05 (0.10%)

May 28, 2026, 4:54 PM CET

Revenue by Geography

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Italy Revenue	329.19M	336.26M
Italy Revenue Growth	-2.10%	6.03%
International Revenue	2.29B	2.01B
International Revenue Growth	14.16%	13.60%
Revenue (Total)	2.62B	2.34B
Revenue (Total) Growth	11.82%	12.45%

Revenue by Geography 2

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Europe Revenue	1.74B	1.65B
Europe Revenue Growth	5.20%	10.59%
Asia and Oceania Revenue	204.76M	156.01M
Asia and Oceania Revenue Growth	31.25%	11.53%
America Revenue	605.34M	477.46M
America Revenue Growth	26.78%	20.92%
Africa Revenue	72.42M	58.03M
Africa Revenue Growth	24.80%	4.52%
Revenue (Total)	2.62B	2.34B
Revenue (Total) Growth	11.82%	12.45%

Revenue Breakdown

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Specialty & Primary Care Revenue	1.54B	1.51B
Specialty & Primary Care Revenue Growth	1.94%	10.24%
Rare Diseases Revenue	1.08B	833.86M
Rare Diseases Revenue Growth	29.69%	16.67%
Revenue (Other)	-	5.00K
Revenue (Total)	2.62B	2.34B
Revenue (Total) Growth	11.82%	12.45%

Revenue Breakdown 2

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Cardiovascular Revenue	396.02M	385.21M
Cardiovascular Revenue Growth	2.81%	5.47%
Urology and Uro-Oncology Revenue	410.05M	399.94M
Urology and Uro-Oncology Revenue Growth	2.53%	42.64%
Gastrointestinal Revenue	238.94M	217.50M
Gastrointestinal Revenue Growth	9.86%	-0.81%
Cough and Cold Revenue	124.30M	137.28M
Cough and Cold Revenue Growth	-9.46%	0.12%
Other Treatment Areas Revenue	308.58M	309.31M
Other Treatment Areas Revenue Growth	-0.24%	-0.74%
Pharmaceutical Chemicals Revenue	59.05M	58.47M
Pharmaceutical Chemicals Revenue Growth	1.00%	8.21%
Hema-Oncology Revenue	414.86M	253.23M
Hema-Oncology Revenue Growth	63.83%	26.08%
Endocrinology Revenue	394.08M	321.69M
Endocrinology Revenue Growth	22.50%	32.75%
Metabolic and Other Areas Revenue	272.51M	258.94M
Metabolic and Other Areas Revenue Growth	5.24%	-4.64%
Revenue (Total)	2.62B	2.34B
Revenue (Total) Growth	11.82%	12.45%

Revenue Breakdown 3

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Pharmaceutical Chemicals Revenue	59.05M	58.47M
Pharmaceutical Chemicals Revenue Growth	1.00%	8.21%
Revenue (Total)	2.62B	2.34B
Revenue (Total) Growth	11.82%	12.45%

EBITDA

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Specialty & Primary Care EBITDA	526.50M	524.44M
Specialty & Primary Care EBITDA Growth	0.39%	12.23%
Rare Diseases EBITDA	464.56M	341.33M
Rare Diseases EBITDA Growth	36.10%	12.89%
Operating Income (Total)	670.81M	638.86M
Operating Income (Total) Growth	5.00%	14.49%

EBIT

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Specialty & Primary Care Operating Income	394.82M	426.73M
Specialty & Primary Care Operating Income Growth	-7.48%	9.92%
Rare Diseases Operating Income	275.99M	212.13M
Rare Diseases Operating Income Growth	30.11%	24.95%
Operating Income (Total)	670.81M	638.86M
Operating Income (Total) Growth	5.00%	14.49%

Key Performance Indicators

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Specialty & Primary Care Like-For-Like Growth	3.80%	5.70%
Rare Diseases Like-For-Like Growth	16.60%	15.70%
Total Like-For-Like Growth	8.30%	9.20%

Updated May 13, 2026. Data Source: Fiscal.ai.